Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDFinch Therapeutics Group, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Finch Therapeutics Group, Inc. Earnings Date And Information
Finch Therapeutics Group, Inc. last posted its earnings results on Thursday, August 10th, 2023. The company reported $-4.33 earnings per share for the quarter, topping analysts' consensus estimates of $-4.51 by $0.18. The company had revenue of 0 for the quarter and had revenue of 107,000 for the year. Finch Therapeutics Group, Inc. has generated $-47 earnings per share over the last year ($-46.59 diluted earnings per share) and currently has a price-to-earnings ratio of -1.59. Finch Therapeutics Group, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
Finch Therapeutics Group, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2024 | Q2 2024 | N/A | -$3.01 | N/A | $0 | $0 |
| 05/10/2024 | Q1 2024 | N/A | -$2.41 | N/A | N/A | $0 |
| 04/26/2024 | Q4 2023 | N/A | -$1.89 | N/A | N/A | $2.85 M |
| 11/08/2023 | Q3 2023 | N/A | -$1.51 | N/A | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$4.51 | -$4.33 | 0.18 | N/A | $0 |
| 05/10/2023 | Q1 2023 | -$2.70 | -$39.89 | -37.19 | N/A | $107,000 |
| 03/23/2023 | Q4 2022 | N/A | -$16.48 | N/A | N/A | $8,000 |
| 11/10/2022 | Q3 2022 | -$12.01 | -$25.21 | -13.2 | $750,000 | $138,000 |
| 08/11/2022 | Q2 2022 | -$13.81 | -$14.36 | -0.55 | $650,000 | $361,000 |
| 05/16/2022 | Q1 2022 | -$0.32 | -$15.50 | -15.18 | N/A | $354,000 |
| 03/31/2022 | Q4 2021 | N/A | -$12.04 | N/A | N/A | $806,000 |
| 11/10/2021 | Q3 2021 | -$12.61 | -$6.29 | 6.32 | N/A | $11.34 M |
| 08/10/2021 | Q2 2021 | -$8.41 | -$9.60 | -1.19 | N/A | $2.83 M |
| 05/13/2021 | Q1 2021 | -$0.24 | -$29.89 | -29.65 | N/A | $3.55 M |
| 12/30/2020 | Q4 2020 | N/A | -$46.85 | N/A | N/A | $1.81 M |
| 09/29/2020 | Q3 2020 | N/A | -$36.65 | N/A | N/A | $1.77 M |
| 06/29/2020 | Q2 2020 | N/A | -$30.71 | N/A | N/A | $2.35 M |
| 03/30/2020 | Q1 2020 | N/A | -$30.13 | N/A | N/A | $1.79 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Finch Therapeutics Group, Inc. Earnings: FAQ's
Finch Therapeutics Group, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based offlast year's report dates.
In the previous quarter, Finch Therapeutics Group, Inc. (:FNCH) reported $-4.33 earnings per share (EPS) to beat the analysts' consensus estimate of $-4.51 by $0.18.
The conference call for Finch Therapeutics Group, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Finch Therapeutics Group, Inc.'s latest earnings report can be read online.
Finch Therapeutics Group, Inc. (:FNCH) has a recorded annual revenue of $107,000.
Finch Therapeutics Group, Inc. (:FNCH) has a recorded net income of $-74,754,000.Finch Therapeutics Group, Inc. has generated $-46.59 earnings per share over the last four quarters.
Finch Therapeutics Group, Inc. (:FNCH) has a price-to-earnings ratio of -1.59 and price/earnings-to-growth ratio is -0.12.